Page 335 - Read Online

Page 8 of 10 Archakova et al. Vessel Plus 2018;2:34 I http://dx.doi.org/10.20517/2574-1209.2018.52

REFERENCES
1. Consultant Doctor. Russian endocrinology clinical recommendations. Available from: http://www.rosmedlib.ru/book/
ISBN9785970436837.html. [Last accessed on 24 Oct 2018] (in Russian)
2. Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia
1997;40:1307-12.
3. Tsujimoto T, Kajio H, Takahashi Y, Kishimoto M, Noto H, et al. Asymptomatic coronary heart disease in patients with type 2 diabetes
with vascular complications: a cross-sectional study. BMJ Open 2011; doi: 10.1136/bmjopen-2011-000139.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the
Multiple Risk Factor Intervention Trial. Diabetes care 1993;16:434-44.
5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, et al. Kidney disease as a risk factor for development of cardiovascular
disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research,
clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154- 69.
6. Dedov II, Shestakova MV. Results of the implementation of the subprogram “diabetes mellitus of the federal target program”
prevention and control of socially significant diseases 2007-2012. Available from: https://cyberleninka.ru/article/n/rezultaty-realizatsii-
podprogrammy-saharnyy-diabet-federalnoy-tselevoy-programmy-preduprezhdenie-i-borba-s-sotsialno-znachimymi. [Last accessed on
24 Oct 2018] (in Russian)
7. Suzuki C, Nakamura S, Ishibashi-Ueda H, Yoshihara F, Kawano Y. Evidence for severe atherosclerotic changes in chronic hemodialysis
patients: comparative autopsy study against cardiovascular disease patients without chronic kidney disease. Ther Apher Dial
2011;15:51-7.
8. Xue JL, Frazier ET, Herzog CA, Collins AJ. Association of heart disease with diabetes and hypertension in patients with ESRD. Am J
Kidney Dis 2005;45:316-23.
9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and
hospitalization. N Engl J Med 2004;351:1296-305.
10. Tanaka M, Yasaka M, Nagano K, Otsubo R, Oe H, et al. Moderate atheroma of the aortic arch and the risk of stroke. Cerebrovasc Dis
2006;21:26-31.
11. Sen S, Oppenheimer SM, Lima J, Cohen B. Risk factors for progression of aortic atheroma in stroke and transient ischemic attack
patients. Stroke 2002;33:930-5.
12. Ku E, Campese V. Is lipid management effective for all stages of CKD? Blood Purif 2013;35:26-30.
13. Bhowmik D, Tiwari SC. Metabolic syndrome and chronic kidney disease. Indian J Nephrol 2008;18:1-4.
14. Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis
patients. Kidney Int 2003;64:1472-9.
15. Gluba A, Olechnowicz-Tietz S, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease.
Int Urol Nephrol 2013;45:1605-12.
16. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol
2006;290:F262-72.
17. Mutluay R, Degertekin CK, Poyraz F, Yılmaz MI, Yücel C, et al. Dialysis type may predict carotid intima media thickness and plaque
presence in end-stage renal disease patients. Adv Ther 2012;29:370-82.
18. Ragino YI, Nikitin YP. Oxidized and structurally-modified low-density lipoproteins in atherosclerosis. Atherosclerosis 2006;2:3-32.
(in Russian)
19. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-478.
20. Medical Theses. Mechanisms and role of atherogenic modification of lipoproteins in atherogenesis. Available from: http://medical-diss.
com/medicina/mehanizmy-i-rol-aterogennoy-modifikatsii-lipoproteidov-v-aterogeneze. [Last accessed on 24 Oct 2018] (in Russian)
21. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, et al. Evidence for the presence of oxidatively modified low
density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
22. Belova LA, Oglobina OG, Belov AA, Kukharchuk VV. Processes of modification of lipoproteins. Physiological and pathogenetical role
of modified lipoproteins. Vopr Med Khim 2000;46:8-21. (in Russian)
23. Sukhorukov VN, Karagodin VP, Orekhov AN. Atherogenic modifications of low-density lipoproteins. Biomed Khim 2016;62:391-402.
(in Russian)
24. Lankin VZ, Konovalova GG, Tikhaze AK, Nedosugova LV. The influence of glucose on the free radical peroxidation of low density
lipoproteins in vitro and in vivo. Biomed Khim 2012;58:339-52. (in Russian)
25. Borodachev EN, Sobenin IA, Karagodin VP, Bobryshev Yu.V, Orekhov A. Multiple modification of low density lipoproteins in diabetes.
Pathogenesis 2013;11:16-21. (in Russian)
26. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, et al. Modification of low density lipoprotein by advanced glycation end
products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994;91:9441-5.
27. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, et al. Coronary-artery calcification in young adults with end-stage renal disease
who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
28. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959-64.
29. Volgina G, Seleznev D, Balkarova O, Lovchinsky E. Extrinsic calcification in patients with CKD. Vrach 2012;7:2-8. (in Russian)